Danaher Co. (NYSE:DHR) Shares Acquired by Telemus Capital LLC

Telemus Capital LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 15.6% during the fourth quarter, HoldingsChannel reports. The firm owned 15,480 shares of the conglomerate’s stock after purchasing an additional 2,085 shares during the quarter. Telemus Capital LLC’s holdings in Danaher were worth $3,581,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after purchasing an additional 3,905,449 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Danaher by 6.5% during the third quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock worth $2,030,327,000 after purchasing an additional 502,868 shares in the last quarter. Northern Trust Corp lifted its position in shares of Danaher by 1.7% during the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock worth $2,009,789,000 after purchasing an additional 134,905 shares in the last quarter. Flossbach Von Storch AG lifted its position in shares of Danaher by 1.8% during the fourth quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock worth $1,064,477,000 after purchasing an additional 82,672 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Danaher by 13.2% in the third quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock valued at $1,009,880,000 after acquiring an additional 473,693 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR opened at $236.08 on Tuesday. The firm has a 50-day moving average price of $248.72 and a 200 day moving average price of $230.39. The firm has a market capitalization of $174.83 billion, a PE ratio of 36.95, a P/E/G ratio of 3.95 and a beta of 0.83. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. Danaher’s revenue was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.87 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is currently 16.90%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent analyst reports. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and upped their price target for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Royal Bank of Canada upped their price target on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Raymond James upped their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. KeyCorp upped their price target on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, Citigroup upped their price target on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $268.27.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last three months, insiders sold 32,957 shares of company stock valued at $8,265,802. 10.90% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.